In the realm of CD47 targeted therapy for ovarian cancer, various approaches have been explored, ranging from monotherapy inhibiting the CD47-SIRPα axis to combinations with tumor-targeting antibodies and bispecific antibodies disrupting the CD47-SIRPα axis (30). The gene discussed is SIRPA; the disease is ovarian carcinoma.